News and Press Releases

CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange

11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024

Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands

Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

2400 Broadway Santa Monica, CA 90404

TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain

The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Beckley Park Beckley OXFORD, OX3 9SY United Kingdom

Altasciences Receives 2024 CRO Leadership Award for Capabilities

16 May 2024 -- Laval, Québec, Canada -- Altasciences announced today that it has been recognised for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This...

Category: BioManufacturing, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada

TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team

3 June 2024 -- Hampshire, UK -- TMC Pharma Services, an established global product development and clinical research organisation (CRO) headquartered in Hampshire, UK, is pleased to announce the appointment...

Category: Clinical Trials, Pharmaceutical
Posted: June 3, 2024

Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK

DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma

88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors

30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...

Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024

3141 Stevens Creek Blvd Suite 40547 San Jose, CA 95117

Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024

Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

New CRO Focused on Cannabis-based Drug Trials Launched

22 May 2024 -- Georgia, US -- Cannovation Clinical Research Partners, a pioneering Cannabis-Based clinical research organisation (CRO) for Drug and Product Development, is proudly announcing its official launch, marking...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: May 22, 2024

3300 Hamilton Mill Rd Ste 102 PMB 3024 Buford, GA 30519

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024

Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

Greenphire Named 2024 “Best Overall Patient Engagement Service” by MedTech Breakthrough Awards

16 May 2024 -- Pennsylvania, US --  Greenphire, a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, has received a 2024 MedTech Breakthrough Award for...

Category: Clinical Trials, Logistics
Posted: May 16, 2024

1018 W. 9th Avenue, Suite 200 King of Prussia, PA 19406

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks

Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...

Category: Biotechnology, Clinical Trials
Posted: May 8, 2024

The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG

Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third

8 May 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship...

Category: Clinical Trials, Other
Posted: May 8, 2024

4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462